E Keppra (levetiracetam) receives regulatory approval in Japan

Otsuka Pharmaceutical and UCB Japan to co-promote E Keppra

26-Jul-2010 - Japan

Otsuka Pharmaceutical Co., Ltd. and UCB announced that UCB Japan has received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra® (250 mg and 500 mg Tablets). E Keppra® has been approved in Japan as adjunctive therapy in the treatment of partial onset seizures, with or without secondary generalisation, in adult patients with epilepsy, who have not obtained sufficient response to other antiepileptic drugs.

Levetiracetam was originally developed by UCB and is now marketed as Keppra® in over 90 countries worldwide. In Japan, it will be marketed under the brand name, E Keppra®. Otsuka Pharmaceutical and UCB will co-promote E Keppra® in Japan.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance